 |
|
|
| |
Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naļve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Eric Lawitz,1 Reem Ghalib,2 Maribel Rodriguez-Torres,3 Zobair M Younossi,4 Ana Corregidor,5 Mark S Sulkowski,6 Edwin DeJesus,7 Brian Pearlman,8 Mordechai Rabinovitz,9 Norman Gitlin,10 Joseph K Lim,11 Paul J Pockros,12 Bart Fevery,13
Tom Lambrecht,14 Sivi Ouwerkerk-Mahadevan,13 Katleen Callewaert,13 William T Symonds,15 Gaston Picchio,16 Karen Lindsay,17 Maria Beumont-Mauviel,13 Ira M Jacobson18
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Medicine and Gastroenterology and Hepatology, The Liver Institute, Dallas, TX, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico, USA; 4Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 5Borland-Groover Clinic, Jacksonville, FL, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Orlando Immunology Center, Orlando, FL, USA; 8Atlanta Medical Center, Atlanta, GA, USA; 9University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 10Atlanta Gastroenterology Association, Atlanta, GA, USA; 11Yale School of Medicine, New Haven, CT, USA; 12Scripps Clinic, La Jolla, CA, USA; 13Janssen Research & Development, Beerse, Belgium; 14Novellas Healthcare, Zellik, Belgium; 15Gilead Sciences Inc, Foster City, CA, USA; 16Janssen Research & Development LLC, Titusville, NJ, USA; 17Formerly of Janssen Research & Development LLC, Titusville, NJ, USA; 18Weill Cornell Medical College, New York, NY, USA
|
| |
|
|
|
|
|
